{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:17:32Z","timestamp":1791584252423,"version":"4.3.4"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.4103","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T04:07:50Z","timestamp":1618978070000},"page":"e214103","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"first","affiliation":[{"name":"Baylor University Medical Center, Dallas, Texas"},{"name":"Texas Oncology, Dallas"},{"name":"US Oncology, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Texas Oncology, Dallas"},{"name":"US Oncology, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wilks","sequence":"additional","affiliation":[{"name":"Texas Oncology, Dallas"},{"name":"US Oncology, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"},{"name":"Rocky Mountain Cancer Centers, Lakewood, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Block","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"},{"name":"Nebraska Cancer Specialists, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andorsky","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"},{"name":"Rocky Mountain Cancer Centers, Boulder, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Danso","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"},{"name":"Virginia Oncology Associates, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Locke","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Scales","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[{"name":"US Oncology, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"6797","key":"zoi210149r1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours.","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"8","key":"zoi210149r2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer.","volume":"360","author":"Sotiriou","year":"2009","journal-title":"N Engl J Med"},{"issue":"7418","key":"zoi210149r3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours.","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"5","key":"zoi210149r4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjh.2011.155.issue-5","article-title":"The potential role of Aurora kinase inhibitors in haematological malignancies.","volume":"155","author":"Farag","year":"2011","journal-title":"Br J Haematol"},{"issue":"49","key":"zoi210149r5","doi-asserted-by":"publisher","first-page":"46219","DOI":"10.1074\/jbc.M107540200","article-title":"Interaction and feedback regulation between STK15\/BTAK\/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle.","volume":"276","author":"Katayama","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"zoi210149r6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1535-7163.MCT-12-0781","article-title":"Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.","volume":"12","author":"Craig","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"zoi210149r7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/onc.2016.292","article-title":"Aurora A kinase activates YAP signaling in triple-negative breast cancer.","volume":"36","author":"Chang","year":"2017","journal-title":"Oncogene"},{"issue":"22","key":"zoi210149r8","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1158\/1078-0432.CCR-10-3357","article-title":"Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.","volume":"17","author":"Sparano","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi210149r9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056919","article-title":"Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer.","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"zoi210149r10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/1471-2407-12-562","article-title":"Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.","volume":"12","author":"Siggelkow","year":"2012","journal-title":"BMC Cancer"},{"issue":"4","key":"zoi210149r12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","article-title":"Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.","volume":"16","author":"Melichar","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi210149r13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/gut.2008.152652","article-title":"Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC.","volume":"58","author":"Calvisi","year":"2009","journal-title":"Gut"},{"issue":"12","key":"zoi210149r14","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1128\/MCB.02364-06","article-title":"MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.","volume":"27","author":"Hoar","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"11","key":"zoi210149r15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1046\/j.1365-2443.2002.00592.x","article-title":"Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells.","volume":"7","author":"Marumoto","year":"2002","journal-title":"Genes Cells"},{"issue":"8","key":"zoi210149r16","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1091\/mbc.e02-11-0769","article-title":"Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis.","volume":"14","author":"Honda","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"3","key":"zoi210149r17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1083\/jcb.200108135","article-title":"Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules.","volume":"156","author":"Giet","year":"2002","journal-title":"J Cell Biol"},{"issue":"9","key":"zoi210149r18","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1158\/1535-7163.MCT-14-0027","article-title":"Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).","volume":"13","author":"Huck","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"zoi210149r19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/mol.108.050492","article-title":"Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.","volume":"75","author":"Pires","year":"2009","journal-title":"Mol Pharmacol"},{"key":"zoi210149r20","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/jco.2013.31.15_suppl.2598","article-title":"Recommended phase (Ph) II dose (RP2D) selection for investigational Aurora A kinase (AAK) inhibitor MLN8237 (Alisertib; A) combined with paclitaxel (P): clinical pharmacokinetics (PK), drug-drug interaction (DDI) assessment, and translational exposure-efficacy modeling.","volume":"31","author":"Venkatakrishnan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi210149r22","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi210149r23","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1038\/onc.2016.490","article-title":"FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"issue":"53","key":"zoi210149r24","doi-asserted-by":"publisher","first-page":"91803","DOI":"10.18632\/oncotarget.v8i53","article-title":"Molecular targeting of the Aurora-A\/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.","volume":"8","author":"Opyrchal","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"zoi210149r25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/bjc.2012.167","article-title":"Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.","volume":"106","author":"Ali","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi210149r26","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3773","article-title":"Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer.","volume":"5","author":"Falchook","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi210149r27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10549-017-4616-7","article-title":"Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.","volume":"168","author":"Haddad","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"zoi210149r29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","article-title":"Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.","volume":"127","author":"Matulonis","year":"2012","journal-title":"Gynecol Oncol"},{"key":"zoi210149r11","author":"Melichar"},{"key":"zoi210149r21","author":"Falchook","year":"2013"},{"key":"zoi210149r28","author":"Haddad","year":"2020"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2778910\/oshaughnessy_2021_oi_210149_1618351387.16224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T04:07:55Z","timestamp":1618978075000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2778910"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.4103","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}